Multiple Dose Pharmacokinetics of Intranasal Ketamine

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Javelin Pharmaceuticals
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Healthy adults

Exclusion Criteria:

• under 18 years